The overall goals of Experimental Therapeutics research at Michigan State University are to identify novel molecular targets for cancer, focus on drug development, and foster interaction between basic, translational, and clinical scientists. Spartans will develop innovative and effective anti-cancer therapies.
Research Topics
- Metabolic and proteasome targets in neuroblastoma (Bachmann)
- New compounds that target pathways for chemoprevention (J. Bernard)
- Polymeric-based drug delivery and tissue engineering platforms in cancer (Chan)
- Superparamagnetic iron oxide nanoparticles (Chen)
- Clinical trials in multiple myeloma (Cole)
- Extracellular vesicles for the targeted delivery of oligonucleotide therapeutics (Harada)
- Immunotherapy and small molecule inhibitor clinical trials in lung cancer (Hrinzenko)
- Targeted drug delivery aided by nanoparticles (Huang)
- Inhibitors of proteasome assembly in multiple myeloma (Isaac)
- Engineering extracellular vesicles as a novel gene delivery tool (Kanada)
- Inorganic nanoparticle and particle engineering for targeted drug delivery (Kim)
- Gene transcription inhibitors with efficacy in melanoma models (Lisabeth)
- Fluorescent molecules that can be manipulated for toxicity against cancer cells (R. Lunt)
- Personalized treatments for cancer-based on metabolic targeting (S. Lunt)
- Small-molecule inhibitors of kinases and autophagy (MacKeigan)
- Nano-patterned substrates for drug screening and therapeutic applications (Mahmoudi)
- Autophagy inhibition as a therapeutic strategy (Martin)
- Bioassay-directed discovery and characterization of natural products (Nair)
- Novel mechanisms to control GPCR function and chemical inhibitors in melanoma (Neubig)
- Chemokine-based immunotherapies to treat cancer (Pyeon)
- Novel nanotechnology-based strategies and therapeutic agents for cancer (Smith)
- Small-molecule binding and docking techniques to understanding target predictions (Wilson)